期刊
CURRENT RHEUMATOLOGY REPORTS
卷 18, 期 3, 页码 -出版社
SPRINGER
DOI: 10.1007/s11926-016-0561-4
关键词
Systemic lupus erythematosus; Infection; Immunosuppression; Microbiome
类别
资金
- AbbVie
- Actelion
- Amgen
- BMS
- Gilead
- GSK
- NIH
- Novartis
- Pfizer
- Roche/Genentech
- UCB
Infection is a leading cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Dysfunction of the innate and adaptive immune systems increases the risk of infection in patients with SLE. Infectious agents have also been theorized to play a role in the pathogenesis of SLE. This article summarizes our current knowledge of the infectious risk SLE patients face as a result of their underlying disease including abnormal phagocytes and T cells as well as the increased risk of infection associated with immunosuppressive agents used to treat disease. Pathogens thought to play a role in the pathogenesis of disease including EBV, CMV, human endogenous retroviruses (HERVs), and tuberculosis will also be reviewed, as well as the pathologic potential of microbial amyloids and the microbiome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据